

RESEARCH BOARD
(Continued from P. 21)

product selection policy.

Chairman of the DRB subcommittee that drew up the resolution is James A. Pittman, Jr., MD, dean of the University of Alabama School of Medicine. Dr. Pittman wrote the "narrative" explanatory statement that goes with the resolution.

Chairman of the full Drug Research Board is Frederick E. Shideman, MD, head of the department of pharmacology, University of Minnesota.

The other members of the DRB are:

Daniel L. Azarnoff, MD, University of Kansas Medical Center.

James A. Bain, PhD, Emory University, Atlanta.

Mitchell B. Balter, PhD, National Institute of Mental Health.

Allan D. Bass, Vanderbilt University medical school, Nashville.

Paul Calabresi, MD, Roger Williams General Hospital, Providence.

J. Richard Crout, MD, director, FDA Bureau of Drugs.

Victor A. Drill, MD, director of scientific and professional affairs, G.D. Searle & Co.

Robert M. Hedges, MD, vice president, research and development, Parke-Davis.

Hugh H. Hussey, MD, editor emeritus, American Medical Association.

Werner Kalow, MD, University of Toronto.

Thomas D. Kinney, MD, Duke University Medical Center, Durham, N.C.

Kenneth G. Kohlstedt, MD, Indiana University Medical School.

Emanuel M. Papper, MD, University of Miami medical school.

James M. Price, MD, vice president, corporate research and experimental therapy, Abbott Labs.

David P. Rall, MD, National Institute of Environmental Health Sciences, Research Triangle Park, N.C.

George W. Thom, MD, Peter Bent Brigham Hospital, Boston.